Core Viewpoint - The company has initiated the first subject enrollment for the Phase I clinical trial of the "Dermatitis Diagnostic Patch 02" aimed at exploring its safety in patients with allergic contact dermatitis in China [1] Group 1: Product Development - The "Dermatitis Diagnostic Patch 02" is designed for patch testing to assist in diagnosing allergic contact dermatitis related to sensitizers such as carso, p-phenylenediamine, and formaldehyde [1] - This product expands the company's research pipeline in the field of allergic disease diagnostics, potentially addressing the allergen detection needs of a broader range of allergic disease patients [1] Group 2: Clinical Trial Progress - The product has officially entered Phase I clinical trials, although the results of these trials carry uncertainties [1] - Subsequent phases, including Phase II, Phase III clinical trials, and the application for market approval, will follow before the product can be commercially available, with progress and outcomes remaining uncertain [1]

Core Insights - Zhejiang Iwu Biological Technology Co., Ltd. has made significant progress in the field of allergic disease diagnostics with the approval of its "Dermatitis Diagnostic Patch 02" for clinical trials by the National Medical Products Administration [1][5] Group 1: Product Development - The "Dermatitis Diagnostic Patch 02" focuses on diagnosing three common allergens: Kathon, p-phenylenediamine, and formaldehyde, which are frequently encountered in daily life and are known to cause allergic contact dermatitis [4][6] - The clinical trial process will follow a rigorous drug development protocol, including Phase I, II, and III trials to assess safety, efficacy, and dosage [5][6] Group 2: Market Position and Impact - Iwu Biological is a leading domestic pharmaceutical company specializing in the research and innovation of allergic disease diagnostics and treatments, with a strong R&D team and a history of successful product launches [6][7] - The approval of the "Dermatitis Diagnostic Patch 02" is expected to enhance the company's competitiveness in the diagnostic market and contribute to the development of the allergic disease diagnostics sector in China [6][7]